ENDRA Life Sciences Inc. reported second quarter 2026 financial results and announced a definitive merger agreement with ASP Isotopes Inc., Noble Africa LLC, and Renergen Limited. Under the transaction, Noble Africa will merge into a subsidiary of ENDRA, surviving as a wholly owned subsidiary, while ENDRA is set to be renamed Noble Africa Inc. The deal includes a concurrent private placement expected to generate approximately $50 million in gross proceeds. Closing is anticipated in the fourth quarter of 2026, subject to stockholder and regulatory approvals. Financially, the company reported net income of approximately $160,000 for the quarter ended June 30, 2026, driven by digital asset gains, compared to a net loss of $1.2 million in the prior year period. Operating expenses totaled $1.5 million, with significant reductions in research and development and sales costs. ENDRA Life Sciences operates in the medical technology industry, pioneering thermoacoustic biomarker imaging for liver disease detection.

ENDRA Life Sciences Inc. received written notice from Nasdaq on July 8, 2026, confirming it has regained compliance with the Minimum Stockholders’ Equity Requirement. The company previously fell below the $2,500,000 minimum threshold reported in its 2025 Annual Report. As a result of regaining compliance, the company will be subject to a Discretionary Panel Monitor for one year starting July 1, 2026. If the company fails to maintain compliance during this monitoring period, Nasdaq may issue a delisting determination without allowing for a standard compliance plan or cure period. ENDRA Life Sciences Inc. is a life sciences company focused on medical technology.

On June 25, 2026, ENDRA Life Sciences Inc. entered into an Agreement and Plan of Merger with ASP Isotopes Inc. (ASPI), Noble Africa LLC, and Renergen Limited. Under the terms, Noble Africa LLC will merge into a subsidiary of ENDRA, with Noble surviving as a wholly-owned subsidiary. Concurrently, Noble will raise approximately $50 million through the sale of Class A and Class B units at $6.57 per unit. ASPI will contribute its equity interest in Renergen to Noble. ENDRA will be renamed Noble Africa Inc. and will implement a dual-class stock structure (Class A and Class B). The merger is subject to stockholder approval and other closing conditions, including ENDRA maintaining a minimum cash balance of $3.8 million. ENDRA operates in the life sciences industry and is transitioning into the energy sector focusing on helium and LNG resources.

ENDRA Life Sciences Inc. announced a proposed merger between its subsidiary and Noble Africa LLC, a subsidiary of ASP Isotopes, Inc. ENDRA Life Sciences Inc. operates in the life sciences industry and develops medical imaging technology.